Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Related Articles
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
Anumana Makes Educated Inferences in Heart Failure
Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical…February 01, 2026
Anumana and Novartis partner for AI-based heart disease detection
NS Medical Devices: Health technology company Anumana has entered into a multi-year strategic collaboration with Novartis Pharmaceuticals to detect heart disease leveraging a series of artificial intelligence (AI)-powered software solutions.…July 13, 2022
AI-guided Detection of Heart Disease in Routine Practice
Med India: Artificial intelligence (AI) screening helps detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published…May 08, 2021